Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder (MATRIX)

Watson Pharmaceuticals

Status and phase: Completed; Phase 4

Conditions: Quality of Life; Urinary Incontinence; Overactive Bladder

Treatments: Drug: oxybutynin transdermal delivery system (Oxytrol(r))

Study type: Interventional

Funder types: Industry

Identifiers

NCT00224146

OXY0402

MATRIX

Details and patient eligibility

About

This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)

Enrollment: 2,878 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency

Exclusion criteria

• Patients for whom Oxytrol(r) is contraindicated.
• Patients treated with Oxytrol(r) prior to participation in this study.
• Patients residing in long-term care facilities or nursing homes.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)